ÂÜÀòÂÒÂ×

Obdulio Piloto received his undergraduate education at Cornell University, majoring in Microbiology. After graduating at the top of his class in 2000, Obdulio went on to further his training at the Johns Hopkins University where he did his graduate thesis research on cancer immunotherapy in the lab of Donald Small MD PhD. Obdulio graduated with his PhD in 2006, then hopped over to the west coast where he pursued post-doctoral research at Stanford University. He further nurtured his interest in clinically relevant research, focusing on small molecule and peptide inhibitors for leukemia. Obdulio’s next stop was Exelixis where as a Research Scientist he managed a team focused on small molecule inhibitors for various diseases. In 2010, Conversant Biologics hired Obdulio as its Chief Scientific Officer. Obdulio transformed Conversant from being a provider of biospecimens into an innovative partner to biotech and pharma companies offering value-added human primary samples and services. Obdulio was part of the Executive team responsible for Conversant being ranked #2 by The Scientist in 2011 for ‘Best Places to Work’. In 2011, Obdulio left Conversant to co-found Entopsis.